Results 121 to 130 of about 333,288 (246)

A nanoluciferase complementation-based assay for monitoring β-arrestin2 recruitment to the dopamine D3 receptor

Biochemistry and Biophysics Reports
Luciferase complementation assays have emerged as a simple means of monitoring receptor-effector interactions in living cells in a time-resolved manner.
Viktor Burström, Kuiying Xu, Emilio Garro-Martínez, Robert H. Mach, Kristoffer Sahlholm, Nibal Betari   +5 more
doaj   +1 more source

Ursodeoxycholic Acid and Parkinson's Disease Risk: An Emulated Target Trial in UK Electronic Health Records

Movement Disorders, EarlyView.
Abstract Background Ursodeoxycholic acid (UDCA) has shown mitochondrial and neuroprotective effects and has been proposed as a treatment for Parkinson's disease (PD). However, population‐level evidence on its effect on PD risk is lacking. Objectives To compare the risk of incident PD among UDCA initiators versus matched non‐initiators within a ...
Chengsheng Ju, Anette Schrag, Camille Carroll, Xi Xiong, James Carpenter, Oliver Bandmann, Thomas Foltynie, Li Wei   +7 more
wiley   +1 more source

Neuropsychiatric and Cognitive Symptom Evolution over the First Decade of Biomarker‐Positive, Sporadic Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Parkinson's disease (PD) is frequently accompanied by neuropsychiatric symptoms (NPS), including cognitive impairment, which often emerge early and co‐occur. Their long‐term evolution remains incompletely characterized, particularly in biomarker‐positive cohorts.
Izabelle Schoen, Jing Wang, Sharon X. Xie, Chelsea Caspell‐Garcia, Eugenia Mamikonyan, Melanie Stark, Nabila Dahodwala, Andrew D. Siderowf, Roseanne Dobkin, Michele K. York, Daniel Weintraub   +10 more
wiley   +1 more source

Sex-based disparities in dopamine agonist response in patients with restless legs syndrome. [PDF]

J Sleep Res
Summary This study aimed to investigate sex‐related differences in the response to ropinirole and pramipexole in patients with restless legs syndrome (RLS). By analysing clinical parameters and polysomnographic (PSG) findings, we sought to elucidate the potential factors related to sex disparities modulating treatment responses and sleep quality in RLS.
Mogavero MP, Antelmi E, Lanza G, Marelli S, Castelnuovo A, Tinazzi M, DelRosso LM, Silvestri R, Ferri R, Ferini Strambi L.   +9 more
europepmc   +2 more sources

Cerebellar Network Organization in Parkinson's Disease: Functional Connectivity across Motor and Cognitive Circuits

Movement Disorders, EarlyView.
Abstract Background The cerebellum is increasingly recognized as a key contributor to cognitive reserve and network organization in Parkinson's disease (PD). However, the relationship of cerebello‐cortical and cerebello‐basal ganglia connectivity with cognitive status and nigrostriatal integrity remains incompletely understood.
Chi‐Ying R. Lin, Thamires N.C. Magalhães, Shayla S. Yonce, Ihika Rampalli, Rory Mahabir, Jessica A. Bernard, and the Parkinson's Precision Medicine Initiative   +6 more
wiley   +1 more source

Dopamine agonist monotherapy utilization in patients with Parkinson's disease. [PDF]

Clin Park Relat Disord, 2023
Frazer M, Arcona S, Le L, Sasane R.
europepmc   +1 more source

Cross‐Cohort Evidence Links KCNJ6 rs702859 to Impulsive–Compulsive Phenotypes in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Impulse control disorders (ICDs) and related compulsive behaviors (CBs) are frequent non‐motor complications of Parkinson's disease (PD) with a probable genetic contribution. Objective To investigate whether genetic variants involved in reward and punishment processing are associated with impulsive–compulsive phenotypes in PD ...
Sergio García‐Díaz, Juan Francisco Martín‐Rodríguez, Laura Muñoz‐Delgado, Rafael Díaz‐Belloso, Silvia Jesús, María Teresa Periñán, Miguel Martín‐Bórnez, Ana M. Castellano‐Guerrero, Elena Ojeda‐Lepe, Daniel Macías‐García, Astrid Adarmes‐Gómez, Dolores Buiza‐Rueda, Marta Bonilla‐Toribio, Elena Iglesias‐Camacho, Manuela San‐Eufrasio, Cristina Pérez‐Calvo, Rocío Pineda‐Sánchez, Francisco Javier Gómez‐Campos, Antonio Luque‐Ambrosiani, Fátima Carrillo‐García, Pilar Gómez‐Garre, Pablo Mir   +21 more
wiley   +1 more source

The FGF/FGFR System in the Biology and Therapeutic Landscape of Pediatric CNS Tumors

Medicinal Research Reviews, EarlyView.
ABSTRACT Central nervous system (CNS) tumors are the most common solid malignancies in children, comprising a highly heterogeneous group of neoplasms defined by distinct molecular alterations and clinical behaviors. Advances in molecular genetics have underscored the relevance of specific signaling pathways in driving pediatric tumorigenesis, among ...
Serena Filiberti, Camilla Tavani, Elena Somenza, Nicolas Tassone, Antonio d'Amati, Marta Turati, Roberto Ronca   +6 more
wiley   +1 more source

Developing the Dopamine D3 Receptor (D3R) Antagonist, (R)‐VK4‐116, as a Non‐Opioid Medication for the Treatment of Opioid Use Disorder

Medicinal Research Reviews, EarlyView.
ABSTRACT Opioid use disorder (OUD) remains a major global health challenge, and currently approved treatments (methadone, buprenorphine, and naltrexone) are all opioid receptor‐targeting drugs with limitations in access, adherence, stigma, and use in polysubstance use disorders. Because the dopamine D3 receptor (D3R) is enriched in limbic brain regions
Chia‐Kuei Wu, Yu‐Chih Lin, Junfeng Huang, Bangwei Ding, Pramod Terse, Rahul Nandre, Haksong Jin, Molly Congdon, Kun Shen, Philip Sanderson, Gregory Tawa, Stephanie Mounaud, Marta De Santis, Donald Lo, Elizabeth A. Ottinger, Amy Hauck Newman   +15 more
wiley   +1 more source

Therapeutic Impact of GLP‐1 Receptor Agonists on Parkinson's Disease: A Scoping Review

Neurology and Clinical Neuroscience, EarlyView.
ABSTRACT No disease‐modifying treatment exists for Parkinson's disease (PD). Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have gained attention as promising candidates for neuroprotection, given documented expression of GLP‐1 receptors within the central nervous system and the contribution of brain insulin resistance to dopaminergic ...
João Pedro Henriques, João Pedro Stringhetta Rahal, Rafael da Cunha Gomes Ribeiro, Enzo Bogucheski Ribeiro Machado, Carlos Antonio Negrato   +4 more
wiley   +1 more source